PRESENTATION

Q3 2025 — Results presentation

Q3 2025PDF · 26 pages3.2 MB
Johnson & Johnson
delivered another strong
performance in the third
quarter fueled by the depth
and strength of our portfolio
and significant progress across
our pipeline. With a sharpened
focus on the six priority areas
of Oncology, Immunology,
Neuroscience, Cardiovascular,
Surgery and Vision, Johnson &
Johnson is in a new era of
accelerated growth and
innovation, with pioneering
treatments that will continue
to transform lives.
3rd Quarter 2025 Results
3rd 	Quarter 2025 Sales
$24.0B 	6.8%
Worldwide increased 	Worldwide increased	Excluding the impact of
translational currency
For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson’s earnings release issued on October 14, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx
1 	Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
2 	Non-GAAP measure; excludes the impact of translational currency.
Note: Values may be rounded
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on
current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements”
included in the Johnson & Johnson earnings release issued on October 14, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
$15.6
billion
Worldwide Innovative Medicine sales
Innovative Medicine worldwide reported sales increased
6.8% or 5.3% operationally2. Stelara impacted results2
by ~(1,070) basis points. Primary operational drivers:
$8.4
billion
Worldwide MedTech sales
MedTech worldwide reported sales
increased 6.8% or 5.6% operationally2
Primary operational drivers:
Shockwave 	Surgical Vision
Joaquin Duato
Chairman & Chief
Executive Officer
Johnson & Johnson Wound Closure
5.4%1
Electrophysiology
Contact Lenses
Adjusted diluted earnings per share1
15.7%	$2.80 Worldwide increased
Stelara impacted results by ~(640) basis points
Diluted earnings per share (EPS)
91.0%	$2.12 Worldwide increased
Biosurgery
Abiomed

-- 1 of 26 --

rd
October 14, 2025

-- 2 of 26 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased
scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent
Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at 	www.sec.gov, 	www.jnj.com, 	www.investor.jnj.com
or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 26 --

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize
for a broad range of indications
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV
Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with
federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
(BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S.
Department of Health and Human Services (HHS)
Infectious Diseases
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Cardiovascular/
Metabolism/Other
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration
with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals,
Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited;
AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from
Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs;
ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Oncology
UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan	Pulmonary Hypertension
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® 	is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Global Public Health
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 26 --

CEO Remarks
Sales performance and earnings review
Cash position and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 26 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 26 --

7
Q3 Earnings summary
1,2
operational sales
growth
Innovative Medicine
MedTech
Strong momentum across the
business
5.3%1,3
operational sales
growth
$15 	billion+
in quarterly sales
for the second time
11
brands growing
double digits
5.6%1
operational sales
growth
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (640) basis point headwind from STELARA
3 	Includes an approximate (1,070) basis point headwind from STELARA

-- 7 of 26 --

Innovative Medicine
8
Oncology 	Neuroscience	Immunology

-- 8 of 26 --

MedTech
9
Addressing one of the largest unmet
needs in healthcare
Advancing the science of surgery and
pioneering what's next
Developing transformational innovations
to improve the health of patients’ eyes
Cardiovascular 	Surgery 	Vision
MedTech Innovation: 	MedTech Innovation: 	MedTech Innovation:
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
OTTAVA
Robotic
Surgical
System
ETHICON 	4000
Surgical Stapler
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
Impella® Heart
Pump Technology

-- 9 of 26 --

Johnson & Johnson’s
intent to separate its
Orthopaedics
business

-- 10 of 26 --

11

-- 11 of 26 --

Darren Snellgrove
Vice President,
Investor Relations

-- 12 of 26 --

% Change
Q3 2024	Q3 2025	Regional sales results 	Operational1
Reported
6.2%	6.2%	$12.9	$13.7	U.S.
4.4	10.7	4.9	5.4	Europe
7.3	4.9	1.2	1.2
Western Hemisphere
(ex U.S.)
3.4	4.0	3.5	3.6	Asia-Pacific, Africa
4.4	7.6	9.6	10.3	International
5.4%	6.8%	$22.5	$24.0	Worldwide (WW)
Dollars in billions
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
3rd Quarter 2025 sales
13

-- 13 of 26 --

$24.0 $22.5
$6.8 $5.9
15.7%; 	12.4%1
$2.80
$2.42
Dollars in billions, except EPS
Reported %; 	Operational %1
Sales
Adjusted earnings2 	Adjusted EPS2
6.8%; 	5.4%1
GAAP earnings
$5.2
$2.7
15.7%
Q3 2025 	Q3 2024
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
3rd Quarter 2025 financial highlights
GAAP EPS
14
Q3 2025 	Q3 2024 	Q3 2025 	Q3 2024
Q3 2025 	Q3 2024 	Q3 2025 	Q3 2024
$2.12
$1.11
91.2% 	91.0%

-- 14 of 26 --

Immunology
$4,168
Infectious Diseases
$829
Neuroscience
$2,024
Oncology
$6,529 CVM/Other
$899
PH
$1,115
■ 	Reported growth 	■ 	Operational growth1
$15,563
6.8%, 	5.3%
WW sales $MM
Key drivers of operational performance1
• 	DARZALEX increase driven by continued strong share gains and market growth
• 	ERLEADA increase driven by market growth and continued share gains, partially offset by the
impact of Part D redesign
• 	CARVYKTI increase driven by continued share gains and site expansion
• 	TECVAYLI and TALVEY growth driven by ongoing launches and continued share gains
• 	RYBREVANT/LAZCLUZE growth driven by ongoing launch and share gains
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to competitive
pressures and the impact of Part D redesign
Oncology
• 	TREMFYA increase due to share gains and market growth, partially offset by unfavorable
patient mix and the impact of Part D redesign
• 	SIMPONI/SIMPONI ARIA growth driven mainly by MSD3 	return of rights in Europe
• 	REMICADE increase due to a one-time favorable patient mix adjustment and MSD3 	return of
rights in Europe
• 	STELARA decline driven by the impact of biosimilar competition and Part D redesign
Immunology
• 	SPRAVATO growth driven by continued increased physician and patient demand
• 	CAPLYTA acquired April 2, 2025
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the
impact of Part D redesign
Neuroscience
• 	UPTRAVI increase driven by market growth and inventory dynamics, partially offset by the
impact of Part D redesign
• 	OPSUMIT/OPSYNVI decline driven by the impact of Part D redesign and unfavorable patient
mix, partially offset by share gains and market growth
Pulmonary
Hypertension (PH)
• 	Declines across the portfolio partially offset by EDURANT growth	Infectious Diseases
• 	XARELTO growth driven by the impact of Part D redesign, partially offset by continued share
loss
Cardiovascular /
Metabolism / Other
(CVM/Other)
Adjusted operational sales2: WW: 3.7%, U.S. 3.3%, Int’l 4.3%
Innovative Medicine highlights – 3rd quarter 2025
WW 6.8%, U.S. 6.0%, Int’l 7.9%	Reported:
WW 5.3%, U.S. 6.0%, Int’l 4.3%	Operational1:
1.7%, 	1.2%
1.1%, 	0.4%
21.3%, 	19.2%
(0.9)%, 	(4.3)%
(9.8)%, 	(10.6)%
Strong operational growth1 of 5.3% driven primarily by Oncology and Neuroscience
15.3%, 	14.6%
15
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	3 	MSD: Merck, Sharp, & Dohme
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	Note: Values may be rounded
Stelara impacted results1 	by ~(1,070) basis points

-- 15 of 26 --

Key drivers of operational performance1
• 	Electrophysiology3: Growth driven by procedure growth, commercial execution, new product
performance (VARIPULSE, TRUPLUSE), strength in mapping, and one-time impacts of installation
and inventory, partially offset by competitive pressures in PFA
• 	Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP
• 	Shockwave: 	Double digit growth driven by Coronary and Peripheral portfolios
Cardiovascular
All platforms impacted by revenue disruption from the previously announced Orthopaedics
transformation:
• 	Hips3: 	Increase driven by new product launches (EMPHASYS)
• 	Trauma3: 	Growth driven by recently launched products (VOLT) partially offset by trade inventory
dynamics and volume-based procurement (VBP) in China
• 	Knees3: 	Increase driven by strength of the ATTUNE portfolio and pull through related to the VELYS
Robotic assisted solutions, partially offset by trade inventory dynamics and VBP in China
• 	Spine, Sports & Other3: 	Reflects competitive pressures and price pressures in the U.S. Early
Interventional segment, partially offset by U.S. spine new product innovations (TriAltis)
• 	Spine: 	~ -3% WW, ~ +1% U.S., ~ -9% Int’l
Orthopaedics
• 	Advanced3
• 	Biosurgery: 	~ +9% growth driven by continued strength of the portfolio and commercial
execution, partially offset by VBP in China
• 	Endocutters: 	~ +3% increase primarily due to commercial execution and new products, partially
offset by VBP in China and competitive pressures
• 	Energy: 	~ -1% due to competitive pressures, Harmonic market decline in the U.S., and VBP in
China, partially offset by go-to-market changes in EMEA
• 	General3: 	Growth primarily due to technology penetration and upgrades within our differentiated
Wound Closure portfolio (Barbed & PLUS Sutures) coupled with commercial execution, partially
offset by softness in OUS aesthetics
Surgery
• 	Contact Lenses/Other: 	Increase driven by market growth, strong performance of the ACUVUE
OASYS 1-Day family, and continued strategic price actions
• 	Surgical: 	Growth driven by strength of recent product innovations (TECNIS PureSee, TECNIS
Odyssey, TECNIS Eyhance), robust demand, and strong commercial execution
Vision
Adjusted operational sales2: WW 5.7%, U.S. 6.8%, Int’l 4.6%
Orthopaedics
$2,274
Surgery
$2,542
Vision
$1,400
Cardiovascular
$2,213
■ 	Reported growth 	■ 	Operational growth1
$8,430
6.8%, 	5.6%
WW sales $MM
Strong operational growth1 of 5.6% due to Cardiovascular, commercial execution, and innovation
WW 6.8%, U.S. 6.6%, Int’l 7.0%	Reported:
WW 5.6%, U.S. 6.6%, Int’l 4.5%	Operational1:
12.6%, 	11.6%
7.7%, 	6.1%
3.8%, 	2.4%
4.4%, 	3.3%
MedTech highlights – 3rd quarter 2025
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	3 	Platforms positively impacted by a one-time reserve adjustment
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website 	Note: Values may be rounded
16

-- 16 of 26 --

%
Increase
(Decrease)
2024	2025
% to Sales	Amount	% to Sales	Amount
6.8	100.0	$22,471	100.0	$23,993	Sales to customers
4.9	31.0	6,963	30.4	7,303	Cost of products sold
7.6	69.0	15,508	69.6	16,690	Gross Profit
8.1	24.3	5,478	24.7	5,922	Selling, marketing and administrative expenses
(25.8)	22.0	4,952	15.3	3,672	Research and development expense
(0.4)	(99)	0.1	18	Interest (income) expense, net
8.0	1,798	(2.0)	(478)	Other (income) expense, net
0.2	41	0.3	63	Restructuring
124.5	14.9	3,338	31.2	7,493	Earnings before provision for taxes on income
263.5	2.9	644	9.7	2,341	Provision for taxes on income
91.2	12.0	$2,694	21.5	$5,152	Net Earnings
-
91.0	$1.11	$2.12	Net earnings per share (Diluted)
2,427.9	2,428.6	Average shares outstanding (Diluted)
19.3%	31.2%	Effective tax rate
.
Adjusted earnings before provision for taxes and net earnings1
15.9	32.4	$7,277	35.2	$8,436	Earnings before provision for taxes on income
15.7	26.1	$5,876	28.3	$6,801	Net earnings
15.7	$2.42	$2.80	Net earnings per share (Diluted)
19.3%	19.4%	Effective tax rate
1 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar and shares in millions except per share figures)
17
3rd Quarter 2025
Condensed consolidated statement of earnings

-- 17 of 26 --

%
Increase
(Decrease)
2024	2025
Innovative Medicine % to Sales	Amount	% to Sales	Amount
6.8	100.0	$14,580	100.0	$15,563	Sales to customers
8.5	19.6	2,852	19.9	3,093	Cost of products sold
6.3	80.4	$11,728	80.1	$12,470	Gross Profit
15.2	17.0	2,491	18.4	2,869	Selling, marketing and administrative expenses
(30.1)	28.9	4,211	18.9	2,944	Research and development expense 	1
(3.4)	(495)	(1.5)	(238)	Other segment items 	2
24.9	37.9	$5,521	44.3	$6,895	Adjusted segment income before tax 	3
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
18
%
Increase
(Decrease)
2024	2025
MedTech % to Sales	Amount	% to Sales	Amount
6.8	100.0	$7,891	100.0	$8,430	Sales to customers
14.4	34.5	2,727	37.0	3,119	Cost of products sold
2.8	65.5	$5,164	63.0	$5,311	Gross Profit
3.0	34.5	2,720	33.2	2,801	Selling, marketing and administrative expenses
6.4	8.7	684	8.6	728	Research and development expense
(1.8)	(141)	0.2	15	Other segment items 	2
(7.0)	24.1	$1,901	21.0	$1,767	Adjusted segment income before tax 	3
%
Increase
(Decrease)
2024	2025
Enterprise % to Sales	Amount	% to Sales	Amount
15.9	32.4	$7,277	35.2	$8,436	Adjusted segment income before tax 	3
3rd Quarter 2025
1 	Includes acquired IPR&D for the global rights to the NM26 bispecific antibody in Q3 2024, totaling $1,250
2 	Other segment items for each reportable segment include charges related to other income and expenses
3 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the 	company's website

-- 18 of 26 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 19 of 26 --

Capital allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q3 2025	Dollars in billions
~$19
Cash and marketable
securities
~($46)	Debt
~($27)	Net debt
~$14	Free cash flow1,2
Q3 2025:
$3.7B 	invested in R&D
$10.4B 	year-to-date
$3.1B 	in dividends paid
to shareholders;
$9.3B 	year-to-date
Note: Values may be rounded
1 	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 	Estimated as of October 14, 2025. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
20

-- 20 of 26 --

Intent to separate our Orthopaedics business
Separation
expected to take
~18-24 months
Represents best path
forward for all
stakeholders
Positions DePuy
Synthes for long-term
success
Further strengthens
focus of J&J as an
innovation
powerhouse
21

-- 21 of 26 --

Increasing operational2 sales guidance to 5.1% and maintaining adjusted operational EPS2,4 at 7.0% (midpoints)
Comments	July 2025	October 2025
Increasing midpoint to 3.8%	3.2% - 3.7%	3.5% - 4.0%	Adjusted operational sales1,2,6
Increasing midpoint by $0.3B to 5.1%
$92.7B - $93.1B
4.5% - 5.0%
$93.0B - $93.4B
4.8% - 5.3%
Operational sales2,6
Increasing midpoint by $0.3B to 5.7%
$93.2B - $93.6B
5.1% - 5.6%
$93.5B - $93.9B
5.4% - 5.9%
Estimated reported sales 	3,6
Maintaining	Increase of ~300 bps	Increase of ~300 bps
Adjusted pre-tax
operating margin4,5
Increasing	$1.0 - $1.2 billion	$1.1 - $1.3 billion	Net other income4
Tightening range due to higher cash balances	$0 - $100 million	$0 - $50 million	Net interest expense / (income)
Increasing due to recently enacted One Big
Beautiful Bill Act
17.0% - 17.5%	17.5% - 18.0%	Effective tax rate4
Maintaining
$10.63 - $10.73
6.5% - 7.5%
$10.63 - $10.73
6.5% - 7.5%
Adjusted EPS (operational)2,4
Maintaining
$10.80 - $10.90
8.2% - 9.2%
$10.80 - $10.90
8.2% - 9.2%
Adjusted EPS (reported)3,4
2025 P&L guidance
1 	Non-GAAP measure; excludes acquisitions and divestitures 	4 	Non-GAAP measure; excludes intangible amortization expense and special items
2 	Non-GAAP measure; excludes the impact of translational currency 	5 	Sales less: COGS, SM&A and R&D expenses
3 	Euro Average Rate: October 2025 = $1.13; Euro Spot Rate: October 2025 = $1.17 	6 	Excludes COVID-19 Vaccine
Note: Values may be rounded 	22

-- 22 of 26 --

Innovative
Medicine
• 	Accelerating sales growth driven by in-market brands and continued progress from recently launched products
• 	Regarding STELARA, HUMIRA erosion curve remains the best proxy1
• 	Icotrokinra approval expected
• 	Accelerating sales growth driven by our continued focus on higher-growth markets
• 	Anticipate continued adoption of newer products as well as new planned launches in 2026
• 	OTTAVA de Novo submission expected
2026 Considerations
MedTech
• 	Expect adjusted earnings per share growth is commensurate with sales growth
• 	Reflects our understanding of the present legislative landscape
• 	Includes current expectations for tariffs, foreign exchange rates, and procedural volumes
P&L
23
1 	Once faced with material biosimilar competition, with the additive impact of Part D re-design

-- 23 of 26 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 24 of 26 --

Slide footer goes here if required 	25

-- 25 of 26 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
P 	US 	SIMPONI (golimumab) 	P 	US 	IMAAVY (nipocalimab 	) 	US 	nipocalimab 	P 	US
INLEXZO (gemcitabine intravesical
system) 	P 	AKEEGA (niraparib/abiraterone) 	P
INLEXZO (gemcitabine intravesical
system)
EU 	Pediatric Ulcerative Colitis
(PURSUIT 2)
EU 	Generalized Myasthenia Gravis
(Vivacity MG3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
STELARA (ustekinumab) 	P 	US 	SPRAVATO (esketamine) 	TREMFYA (guselkumab) 	P 	US 	AKEEGA (niraparib/abiraterone) 	P 	RYBREVANT / LAZCLUZE 	RYBREVANT (amivantamab)
P 	EU 	Pediatric Crohn's Disease (UNITI
JR)
Treatment Resistant Depression
monotherapy (TRD4005)
P 	EU 	Ulcerative Colitis Subcutaneous
Induction (ASTRO)
P 	EU 	M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Small Cell Lung Cancer (MARIPOSA
Final OS)
Head and Neck Cancer (ORIGAMI-4)
P 	US 	TREMFYA (guselkumab) 	US 	CAPLYTA (lumateperone) 	P 	US 	TREMFYA (guselkumab) 	P 	TREMFYA (guselkumab) 	P 	TALVEY + TECVAYLI
Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Adjunctive Treatment for Major
Depressive Disorder
Psoriatic Arthritis Structural
Damage (APEX)
Ulcerative Colitis Subcutaneous Induction
(ASTRO)
Multiple Myeloma
Relapsed/Refractory (RedirecTT-1)
P 	US 	TREMFYA (guselkumab) 	US 	DARZALEX (daratumumab) 	TREMFYA (guselkumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-4496
P 	EU 	Crohn's Disease Subcutaneous
Induction (GRAVITI)
P 	EU 	Smoldering Multiple Myeloma
(AQUILA)
P 	EU 	Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis Structural Damage
(APEX)
Hematological Malignancies
(LYM1001)
P 	US 	TREMFYA (guselkumab) 	US 	DARZALEX (daratumumab) 	US 	STELARA (ustekinumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-5322
Pediatric Psoriasis
(PROTOSTAR)
P 	EU 	Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU 	Pediatric Ulcerative Colitis
(UNIFI JR)
Pediatric Psoriasis (PROTOSTAR) 	Multiple Myeloma (MMY1001)
P 	US 	TREMFYA (guselkumab) 	P 	US
INLEXZO (gemcitabine
intravesical system) 	P 	US 	STELARA (ustekinumab) 	P 	icotrokinra 	P 	RYBREVANT (amivantamab)
Pediatric Juvenile Psoriatic
Arthritis
Non Muscle Invasive Bladder
Cancer (SunRISe-1)
Pediatric Crohn's Disease (UNITI
JR)
Psoriasis (ICONIC-LEAD) 	Colorectal Cancer (ORIGAMI-1 right-
sided)
P 	US 	TREMFYA (guselkumab) 	US 	RYBREVANT (amivantamab) 	P 	US 	icotrokinra 	P 	icotrokinra 	P 	JNJ-8343
P 	EU 	Crohn's Disease (GALAXI) 	P 	EU 	Subcutaneous (PALOMA-3) 	P 	EU 	Psoriasis (ICONIC) 	Psoriasis (ICONIC-TOTAL) 	Prostate Cancer (PCR1001)
TREMFYA (guselkumab) 	IMBRUVICA (ibrutinib) 	P 	icotrokinra 	JNJ-4804 Co-antibody Therapy
P 	EU 	Ulcerative Colitis (QUASAR) 	EU 	Frontline MCL (Triangle) 	Psoriasis (ICONIC-Advance1/2) 	Psoriatic Arthritis (AFFINITY)
P 	US 	IMAAVY (nipocalimab 	) 	P 	aticaprant 	P 	icotrokinra
Generalized Myasthenia Gravis
Pediatrics (VIBRANCE MG)
Adjunctive Treatment for Major Depressive
Disorder with Anhedonia (Ventura 1)
Ulcerative Colitis (ANTHEM)
P 	RPGR Gene Therapy 	nipocalimab 	Combination Therapy
Retinitis Pigmentosa (LUMEOS) 	Rheumatoid Arthritis (DAISY)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2025*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and
does not guarantee continued investment. This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= 	Achieved

-- 26 of 26 --